Context Therapeutics expands share offering program to $75 million

Context Therapeutics Inc. (NASDAQ: CNTX) amended its at-the-market equity offering program on October 24, 2025, expanding the aggregate offering amount to $75 million from its previous limit, according to a company statement.

The biotechnology company entered into Amendment No. 1 to its existing Sales Agreement with Leerink Partners LLC, which serves as the sales agent for the program. Under the amended agreement, Context Therapeutics may offer and sell shares worth up to $75 million, excluding shares previously sold under the prior prospectus.

As of October 24, 2025, the company had sold 14,705,882 shares under the previous arrangement at an aggregate offering price of approximately $15 million. The amendment allows the company to continue selling shares through a new registration statement filed with the Securities and Exchange Commission that became effective on November 14, 2024.

Sales under the program are conducted as at-the-market offerings, where Leerink Partners will use commercially reasonable efforts to sell shares. The agent receives a commission of up to 3.0% of gross proceeds from share sales, and Context Therapeutics has agreed to reimburse certain expenses related to the amendment.

The company plans to use net proceeds from the offering for research and development of its product candidates, working capital, and general corporate purposes, which may include acquiring additional assets.

You May Also Be Interested In

• Hertz prices share lending deal tied to new debt offering
• Oracle adds 10 companies to its defense technology ecosystem
• Teledyne MEMS expands Edmonton facility with CA$620K grant